ArticleCancer medicine2026
Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III-N2 Driver Gene-Negative Non-Small Cell Lung Cancer in the Immunotherapy Era.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundComparisons among treatment strategies for potentially resectable Stage III-N2 driver gene-negative non-small cell lung cancer (NSCLC) remain limited. We evaluated three treatment strategies-neoadjuvant chemoimmunotherapy followed by surgery (NCIT+surgery), NCIT followed by chemoradiotherapy (NCIT+CRT), and definitive concurrent chemoradiotherapy followed by immunotherapy (CRT + IT)-to investigate whether CRT could represent a feasible option to surgery.
methodsPatients with Stage III-N2 NSCLC from two institutions (2019-2024) were retrospectively enrolled. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Subgroup analyses included metastatic N2 lymph node status, stage, programmed death ligand 1 expression, radiographic response to NCIT, and adjuvant or consolidation immunotherapy after surgery or CRT. Baseline differences were balanced 1:1 by propensity score matching (PSM). Survival was estimated by the Kaplan-Meier method and compared via the log-rank test.
resultsA total of 363 patients were included: NCIT+Surgery (n = 176), NCIT+CRT (n = 55), and CRT + IT (n = 132). The median follow-up time was 31.5 months. Before and after PSM, PFS, and OS were longer in NCIT+Surgery than in CRT + IT, whereas no significant difference was observed between NCIT+Surgery and NCIT+CRT. Subgroup analysis showed that survival did not differ significantly between NCIT+Surgery and CRT + IT in patients with multistation or bulky N2 metastasis, whereas CRT + IT was associated with inferior PFS and OS in patients without these features.
conclusionsSurvival did not differ significantly between CRT and surgery after NCIT, nor between CRT + IT and NCIT + Surgery among patients with multistation or bulky N2 disease. Whether CRT can serve as an alternative to surgery in this population requires validation in large-scale prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.